How We Got Here—A Short History of Invisibility
- Protective rules: After past harms (some medicines caused birth defects), rules were tightened and often excluded people who could become pregnant. That reduced risk — but it also reduced what we learned about how treatments affect women.
- Simpler studies, lower cost: Research that includes many different groups (ages, races, genders) is more complex and expensive. Some studies used narrower groups to save time and money.
- Who decides matters: Scientists, funders, and policymakers historically came from similar backgrounds. Their priorities shaped which questions were asked and who was invited to participate.
These choices created a pattern: many studies didn’t include enough women or enough people from diverse backgrounds, and that left gaps in medical knowledge.
Three Root Causes:
| Era | Reason for Exclusion | Consequence |
|---|---|---|
| 1950s-80s | “Protecting women” (after thalidomide caused birth defects) | Pregnant/lactating women banned → No safety data for 50% of adults |
| 1990s-2000s | Cost/logistics | Trials favored white males: Easier to recruit near urban hospitals |
| Today | Unconscious bias | Researchers design studies for “standard” bodies (often their own) |
The domino effect:
Exclusion → Flawed data → Guidelines based on partial truth → Real people suffer.
How people are affected — concrete examples
Example 1 — Different symptoms, missed diagnosis
When Laila arrived at the emergency room with breathlessness and nausea (not chest pain). ER staff dismissed her—"just anxiety."
Why? Heart attack studies enrolled 80% men.
Women’s symptoms were never documented. Because women’s heart attack symptoms can be different, her condition wasn’t recognised immediately.
Delay in diagnosis can mean worse outcomes.
“Key point: Diagnostic guides built from one population can miss others.“
Example 2 — Medicines that behave differently
A painkiller tested mainly in men is prescribed to women. After consumption, many women report stronger side effects and longer recovery.
Why? Women metabolise some medicines slower than men—but early trials used male subjects.
Investigations show women’s bodies process the drug differently, so the dose or warnings should differ.
“Key point: Drugs often interact with bodies differently depending on sex, age, body size and genetics.“
Example 3 — No clear guidance for pregnancy
Because pregnant people were often excluded from trials, when a pregnant person needs a medication, clinicians must make decisions without solid evidence — leading to uncertainty and variation in care.
“Key point: Excluding a group for “safety” can leave them with no safe, evidence-based options.”
Example 4 — Compounded disadvantage
A Black older woman living in a rural area may face multiple barriers at once: less access to specialists, fewer clinical studies that include people of her age and race, and economic constraints that make follow-up care harder. The combination of race, age and location changes how health problems appear and how they should be treated.
"Key point: Effects are rarely due to a single factor — gender, race, age, location and income all intersect."
"The pattern: No ill intent—just incomplete science."